GlassScriptPhysician profile
Jane Mackay Manly
NPI 1558429118
$9,164.93
in general payments reported to CMS, 2019-2025
16 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $31.93 · 2021: $381 · 2022: $1,333 · 2023: $1,746 · 2024: $3,649 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,589 · Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,588.50 |
| Food and Beverage | $2,647.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $7,467.94 | 2022-2025 | Cvi Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Lkc Technologies, INC. | $269.38 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.08 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $213.37 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $189.09 | 2022 | |
| Alcon Vision LLC | $137.05 | 2021-2025 | Precision7 |
| Novartis Pharmaceuticals Corporation | $118.92 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $114.71 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $107.20 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $103.40 | 2024 | Syfovre |
| Allergan, INC. | $97.00 | 2022 | |
| Sight Sciences, INC. | $33.61 | 2022 | |
| Aerie Pharmaceuticals, INC. | $33.50 | 2021 | |
| Sun Pharmaceutical Industries INC. | $29.07 | 2019 | |
| Abbvie INC. | $20.32 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Manly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.